Year: 2016
Type: article
Abstract: I n the five decades since the completion of the Greenberg Report recommendations in 1967 (which were later published 1 ), independent groups of experts have monitored the progress of many clinical trials for early definitive evidence of benefit, convincing evidence of harm, or sufficient evidence of no potential benefit to render continuation of the trial to be futile.Such monitoring is motivated primarily by an ethical imperative; for trials of treatments intended to prevent or delay serious outcomes, one would want to stop the trial and make the superior treatment available as soon as the evidence was definitive.The assessment of risk versus benefit throughout the course of the trial requires frequent access to accumulating data on efficacy and safety.To allow investigators and sponsors to manage the trial without bias, as well as to ensure an objective assessment of the accumulating data, independent committees, known as data monitoring committees (DMCs), data and safety monitoring boards, or other aliases, 2 are established to perform this monitoring function and to make recommendations regarding trial modifications, including early termination, to investigators and sponsors.These committees require multidisciplinary expertise and experience, including knowledge of statistical methods for interim data monitoring; they also pay attention to recruitment progress and the general quality of the trial with respect to adherence to the protocol and completeness of data collection and follow-up.Data are typically reviewed by DMCs according to the intervention groups as randomized; these groups should be identified fully, perhaps as "group A and group B," in the printed report, in which the identities of groups A and B are known by the DMC.[2][3][4] After the data have been reviewed, DMCs make a recommendation to the trial steering committee that the trial continue as planned or be terminated early for the reasons noted above (see Table 1 for a summary of DMC responsibilities).The Coronary Drug Project, an early, large cardiovascular trial sponsored by what was at that time known as the National Heart Institute, was probably the first trial to incorporate interim review by independent experts 5 and provided many lessons regarding the DMC process.6,7 This process continued to evolve and became the general approach for most federally sponsored randomized trials during the 1970s 2,8,9 and eventually for the increasing number of phase 3 industry-sponsored trials, 10 with some modification of the National Institutes of Health (NIH) model.11 The evolution of DMCs continues as the art and science of clinical trial performance itself evolves.In most cases, trials are completed as planned, with no DMC recommendation for early termination or major modification, but some trials have raised challenging issues for DMCs.[12][13][14][15][16][17][18][19] In this article, we briefly summarize a few classic cases of early termination and then address some recent cases to further illustrate the complexity of the responsibilities of the DMCs.
Source: New England Journal of Medicine
Authors: David L. DeMets, Susan S. Ellenberg
Institutions: University of Wisconsin–Madison, University of Pennsylvania
Language: English
Subfield: Statistics and Probability
Field: Mathematics
Domain: Physical Sciences
Open Access status: bronze
OpenAlex ID: W2529207539
